← Back to Search

Vasopressor

Vasopressin vs Phenylephrine for Preventing Kidney Injury During Cardiac Surgery

Phase 4
Recruiting
Research Sponsored by Thomas Jefferson University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days
Awards & highlights

Summary

This trial compares two drugs to maintain blood pressure during cardiac surgery. Primary outcome is kidney injury; secondary outcomes include mortality, stroke, etc.

Who is the study for?
Adults over 18 years old who are undergoing coronary artery bypass graft, valve surgery, or both can join this trial. It's not for those with severe heart pump issues (ejection fraction <35%), significant lung blood pressure problems, certain heart muscle dysfunction, planned use of a radial artery in the surgery, or if they need to stop their circulation during the operation.
What is being tested?
The study is comparing two drugs—Vasopressin and Phenylephrine—to see which one is better at preventing kidney injury when used as the first choice drug to maintain blood pressure during and after heart surgery. Participants will be randomly assigned to one of these treatments.
What are the potential side effects?
Possible side effects from Vasopressin include chest pain, fast heartbeat, skin paleness while Phenylephrine may cause headache, high blood pressure, and reflex bradycardia (slowing down of the heart).

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of patients with acute kidney injury
Secondary study objectives
ICU Length of Stay
Number of patients with 30-Day Mortality
Number of patients with Atrial Fibrilation
+3 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: VasopressinExperimental Treatment1 Intervention
Low dose vasopressin as first line vasopressor in cardiac surgery.
Group II: PhenylephrineExperimental Treatment1 Intervention
Low dose phenylephrine as first line vasopressor in cardiac surgery
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Vasopressin
FDA approved
Phenylephrine
FDA approved

Find a Location

Who is running the clinical trial?

Thomas Jefferson UniversityLead Sponsor
457 Previous Clinical Trials
149,876 Total Patients Enrolled
1 Trials studying Acute Kidney Injury
450 Patients Enrolled for Acute Kidney Injury

Media Library

Phenylephrine (Vasopressor) Clinical Trial Eligibility Overview. Trial Name: NCT04602767 — Phase 4
Acute Kidney Injury Research Study Groups: Vasopressin, Phenylephrine
Acute Kidney Injury Clinical Trial 2023: Phenylephrine Highlights & Side Effects. Trial Name: NCT04602767 — Phase 4
Phenylephrine (Vasopressor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04602767 — Phase 4
~61 spots leftby Oct 2025